Significant breakthrough in understanding the evolution of the universe. Research by the Atacama Cosmology Telescope collaboration has culminated in a groundbreaking new image that reveals the most detailed map of dark matter distributed across a quarter of the entire sky, reaching deep into the cosmos. Findings provide further support to Einstein’s theory of general relativity, which has been the foundation of the standard model of cosmology for more than a century, and offers new methods to demystify dark matter.

For millennia, humans have been fascinated by the mysteries of the cosmos.

Unlike ancient philosophers imagining the universe’s origi...

Researchers have developed a way to create photonic time crystals and shown that these bizarre, artificial materials amplify the light that shines on them. These findings, described in a paper in Science Advances, could lead to more efficient and robust wireless communications and significantly improved lasers.

Time crystals were first conceived by Nobel laureate Frank Wilczek in 2012. Mundane, familiar crystals have a structural pattern that repeats in space, but in a time crystal, the pattern repeats in time instead. While some physicists were initially sceptical that time crystals could exist, recent experiments have succeeding in creating them...

The 2D map of this ‘disk wind’ may reveal clues to galaxy formation.

Astronomers have mapped the ‘disk winds’ associated with the accretion disk around Hercules X-1, a system in which a neutron star is drawing material away from a sun-like star. The findings may offer clues to how supermassive black holes shape entire galaxies.

An accretion disk is a colossal whirlpool o...

A new drug, a monoclonal antibody known as enoblituzumab, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body, according to a phase 2 study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy. If confirmed in additional studies, enoblituzumab could become the first promising antibody-based immunotherapy agent against prostate cancer.

In a clinical trial, 32 men with high-risk or very high-risk prostate cancers who were scheduled for prostate cancer surgery were treated with six weekly infusions of enoblituzumab prior to surgery, and were followed fo...